文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

巴姆兰尼单抗单药或联合依替昔单抗对轻中度COVID-19患者病毒载量的影响:一项随机临床试验

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

BLAZE-1试验纳入613例轻中度COVID-19门诊患者,随机接受巴姆兰尼单抗单药(700/2800/7000 mg)、巴姆兰尼单抗2800 mg联合依替昔单抗2800 mg或安慰剂单次输注。

要点

  • 联合治疗组第11天病毒载量较安慰剂显著降低,差异有统计学意义。
  • 巴姆兰尼单抗单药三个剂量组病毒载量降低均与安慰剂无显著差异。
  • 联合治疗组COVID-19相关住院或急诊就诊比例为0.9%,安慰剂组为5.8%。

核心结论

  • 在非住院轻中度COVID-19患者中,巴姆兰尼单抗联合依替昔单抗较安慰剂显著降低第11天SARS-CoV-2病毒载量,而巴姆兰尼单抗单药无显著差异。

研究设计与样本

  • BLAZE-1为随机2/3期试验,在美国49个中心纳入613例SARS-CoV-2阳性且至少有1项轻中度症状的门诊患者。
  • 患者随机接受巴姆兰尼单抗700 mg(n=101)、2800 mg(n=107)、7000 mg(n=101)、巴姆兰尼单抗2800 mg联合依替昔单抗2800 mg(n=112)或安慰剂(n=156)单次输注。
  • 最终分析纳入577例实际接受输注的患者,平均年龄44.7岁(SD 15.7),女性315例(54.6%),533例(92.4%)完成第29天疗效评估。

主要发现

  • 第11天病毒载量较基线变化:700 mg组-3.72,2800 mg组-4.08,7000 mg组-3.49,联合治疗组-4.37,安慰剂组-3.80。
  • 84个次要终点中有10个在治疗组与安慰剂组间差异有统计学意义。
  • COVID-19相关住院或急诊就诊比例:安慰剂组5.8%(9例),700 mg组1.0%(1例),2800 mg组1.9%(2例),7000 mg组2.0%(2例),联合治疗组0.9%(1例)。
  • 即刻超敏反应共报告9例(巴姆兰尼单抗6例,联合治疗2例,安慰剂1例),研究治疗期间无死亡。

临床怎么用

  • 对于非住院轻中度COVID-19患者,巴姆兰尼单抗联合依替昔单抗可显著降低第11天病毒载量,单药治疗未显示显著病毒载量降低。

局限性

  • 主要终点为病毒载量变化,临床获益仍需以临床结局为主要终点的进一步试验评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19. OBJECTIVE: To determine the effect of bamlanivimab monotherapy and combination therapy with bamlanivimab and etesevimab on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in mild to moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: The BLAZE-1 study is a randomized phase 2/3 trial at 49 US centers including ambulatory patients (N = 613) who tested positive for SARS-CoV-2 infection and had 1 or more mild to moderate symptoms. Patients who received bamlanivimab monotherapy or placebo were enrolled first (June 17-August 21, 2020) followed by patients who received bamlanivimab and etesevimab or placebo (August 22-September 3). These are the final analyses and represent findings through October 6, 2020. INTERVENTIONS: Patients were randomized to receive a single infusion of bamlanivimab (700 mg [n = 101], 2800 mg [n = 107], or 7000 mg [n = 101]), the combination treatment (2800 mg of bamlanivimab and 2800 mg of etesevimab [n = 112]), or placebo (n = 156). MAIN OUTCOMES AND MEASURES: The primary end point was change in SARS-CoV-2 log viral load at day 11 (±4 days). Nine prespecified secondary outcome measures were evaluated with comparisons between each treatment group and placebo, and included 3 other measures of viral load, 5 on symptoms, and 1 measure of clinical outcome (the proportion of patients with a COVID-19-related hospitalization, an emergency department [ED] visit, or death at day 29). RESULTS: Among the 577 patients who were randomized and received an infusion (mean age, 44.7 [SD, 15.7] years; 315 [54.6%] women), 533 (92.4%) completed the efficacy evaluation period (day 29). The change in log viral load from baseline at day 11 was -3.72 for 700 mg, -4.08 for 2800 mg, -3.49 for 7000 mg, -4.37 for combination treatment, and -3.80 for placebo. Compared with placebo, the differences in the change in log viral load at day 11 were 0.09 (95% CI, -0.35 to 0.52; P = .69) for 700 mg, -0.27 (95% CI, -0.71 to 0.16; P = .21) for 2800 mg, 0.31 (95% CI, -0.13 to 0.76; P = .16) for 7000 mg, and -0.57 (95% CI, -1.00 to -0.14; P = .01) for combination treatment. Among the secondary outcome measures, differences between each treatment group vs the placebo group were statistically significant for 10 of 84 end points. The proportion of patients with COVID-19-related hospitalizations or ED visits was 5.8% (9 events) for placebo, 1.0% (1 event) for 700 mg, 1.9% (2 events) for 2800 mg, 2.0% (2 events) for 7000 mg, and 0.9% (1 event) for combination treatment. Immediate hypersensitivity reactions were reported in 9 patients (6 bamlanivimab, 2 combination treatment, and 1 placebo). No deaths occurred during the study treatment. CONCLUSIONS AND RELEVANCE: Among nonhospitalized patients with mild to moderate COVID-19 illness, treatment with bamlanivimab and etesevimab, compared with placebo, was associated with a statistically significant reduction in SARS-CoV-2 viral load at day 11; no significant difference in viral load reduction was observed for bamlanivimab monotherapy. Further ongoing clinical trials will focus on assessing the clinical benefit of antispike neutralizing antibodies in patients with COVID-19 as a primary end point. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04427501.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021. PMID: 33475701. doi:10.1001/jama.2021.0202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。